Contact information
Research groups
David Kerr
CBE FMedSci FRCP
Professor of Cancer Medicine
- Consultant Physician
Genetics and Genomics
In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.
Key publications
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Recent publications
-
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
Journal article
Le Teuff G. et al, (2024), Br J Cancer
-
Personalizing adjuvant therapy for patients with colorectal cancer.
Journal article
Yang L. et al, (2023), Nat Rev Clin Oncol
-
Data from GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner
Other
Wang Z. et al, (2023)
-
Data from GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner
Other
Wang Z. et al, (2023)
-
Supplementary Data from GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner
Other
Wang Z. et al, (2023)